Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    15
    ...
ATC Name B/G Ingredients Dosage Form Price
N05AH03 APO-OLANZAPINE ODT G Olanzapine - 10mg 10mg Tablet, orally disintegrating 2,422,948 L.L
A04AA01 APO-ONDANSETRON G Ondansetron - 8mg 8mg Tablet 1,491,665 L.L
N06AB05 APO-PAROXETINE G Paroxetine (HCl) - 20mg 20mg Tablet 983,693 L.L
C10AA03 APO-PRAVASTATIN G Pravastatin Sodium - 40mg 40mg Tablet 958,160 L.L
C10AA03 APO-PRAVASTATIN G Pravastatin Sodium - 20mg 20mg Tablet 775,397 L.L
C07AA05 APO-PROPRANOLOL G Propranolol HCl - 10mg 10mg Tablet, scored 280,863 L.L
C07AA05 APO-PROPRANOLOL G Propranolol HCl - 40mg 40mg Tablet, scored 356,118 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 2.5mg 2.5mg Capsule 463,626 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 5mg 5mg Capsule 794,211 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 10mg 10mg Capsule 1,178,550 L.L
M05BA07 APO-RISEDRONATE G Risedronate sodium - 150mg 150mg Tablet 1,034,759 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 670,577 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 670,577 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 40mg 40mg Tablet 670,577 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 20mg 20mg Tablet 1,111,358 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 5mg 5mg Tablet 1,635,456 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 10mg 10mg Tablet 888,280 L.L
G04CA02 APO-TAMSULOSIN CR G Tamsulosin HCl - 0.4mg 0.4mg Tablet 607,417 L.L
D01BA02 APO-TERBINAFINE G Terbinafine HCl - 250mg 250mg Tablet 1,409,691 L.L
R06AX13 APOTHECARE LORATADINE G Loratadine - 10mg 10mg Tablet 430,030 L.L
A04AD12 APREPITANT BIOGARAN G Aprepitant - 80mg 80mg Capsule 2,164,930 L.L
A04AD12 APREPITANT BIOGARAN 125MG APREPITANT BIOGARAN 80MG G Aprepitant - 125mg, Aprepitant - 80mg 125mg Capsule 3,246,723 L.L
L04AA32 APRIVA G Apremilast - 30mg 30mg Tablet, film coated 41,455,526 L.L
L04AA32 APRIVA STARTER PACK G Apremilast - 10mg, Apremilast - 20mg, Apremilast - 30mg Tablet, film coated 22,154,866 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
M01AB16 ARACENAC G Aceclofenac - 100mg 100mg Tablet, film coated 330,585 L.L
J06BA02 ARAGAM BioHuman Human normal immunoglobulin - 5g/100ml 5g/100ml Injectable solution 40,075,575 L.L
    ...
    15
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025